U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $225 billion and an impressive 82% gross profit margin according to InvestingPro, has announced the U.S. Food and Drug Administration (FDA) approval of its drug Imfinzi as a perioperative treatment for muscle-invasive bladder cancer (MIBC). This approval, granted today, marks Imfinzi as the first immunotherapy for patients in this setting. The FDA’s decision was based on the NIAGARA Phase III trial results, which demonstrated significant improvements in both survival rates and disease recurrence reduction when compared to chemotherapy alone.
The NIAGARA trial, which included over 1,000 participants, revealed a 32% decrease in the risk of disease progression or death and a 25% reduction in the risk of death for those treated with Imfinzi in combination with chemotherapy, followed by Imfinzi as a standalone post-surgery treatment. This breakthrough comes as AstraZeneca (NASDAQ:AZN) maintains strong momentum, with revenue growth of 18% in the last twelve months and a robust research pipeline. For detailed analysis and more insights, check out the comprehensive Pro Research Report available on InvestingPro. Notably, approximately 80% of patients treated with the Imfinzi regimen were still alive after two years.
Matthew ND. Galsky, a key investigator in the NIAGARA trial, emphasized the breakthrough nature of this approval, highlighting the potential to transform the standard of care for MIBC patients. Dave Fredrickson, Executive Vice President at AstraZeneca, echoed this sentiment, pointing out the paradigm shift in treatment options for these patients.
The Bladder Cancer Advocacy Network welcomed the news, emphasizing the need for improved treatment options. The approval follows the inclusion of the Imfinzi regimen in the NCCN Clinical Practical Guidelines in Oncology as a recommended treatment for MIBC.
Imfinzi works by targeting the PD-L1 protein, releasing the inhibition of immune responses and allowing the body to attack tumor cells. This drug is part of AstraZeneca’s broader effort to redefine cancer care and deliver life-changing medicines to patients.
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, with a particular emphasis on Oncology, Rare Diseases, and BioPharmaceuticals. The company’s financial health is rated as "GREAT" by InvestingPro, with a 33-year track record of consistent dividend payments and strong cash flows. This announcement is based on a press release statement. Investors can access 8 additional exclusive ProTips and comprehensive financial metrics through InvestingPro’s advanced analytics platform.
In other recent news, AstraZeneca has received U.S. FDA approval for its drug IMFINZI, intended for the treatment of adult patients with muscle-invasive bladder cancer. The approval is based on results from the Phase III NIAGARA trial, which showed a 25% reduction in the risk of death when IMFINZI was used in combination with gemcitabine and cisplatin, followed by IMFINZI monotherapy after surgery. This development introduces a new standard of care for patients in the U.S., marking a significant advancement in treatment options. Meanwhile, Goldman Sachs has maintained its Conviction Buy rating on AstraZeneca, with a price target of $98, highlighting the potential growth in the oral PCSK9 inhibitor market. The firm is optimistic about AstraZeneca’s AZD0780, which is central to upcoming trial data expected to impact the cardiovascular drug landscape. Additionally, several European pharmaceutical companies, including AstraZeneca, have reportedly expedited shipments of medicines to the U.S. due to potential tariff threats from President Donald Trump. This precautionary measure aims to mitigate any disruptions that might arise from anticipated tariffs on European-manufactured products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.